Nuvectis Pharma

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12th, 2022 at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists from the Pediatric Solid Tumour Biology and Therapeutics Team led by Prof. Louis Chesler of The Institute of Cancer Research in London, UK, in collaboration with the Institute of Genetics & Cancer at The University of Edinburgh.

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation of NXP900 that took place yesterday at the American Association for Cancer Research (“AACR”) Conference in New Orleans.

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference

Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the oral presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Conference in New Orleans.  The presentor, Prof. Paul Workman, is head of the NXP800 program at, and former CEO of, The Institute of Cancer Research, London, UK.

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference

Complet ed Initial Public Offering in February 202 2 , R aising $16.0 million in G ross P roceeds

Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights

Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to NXP800 has been selected for an oral presentation and an abstract related to NXP900 has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Meeting (2022 AACR), taking place from April 8th to April 13th in New Orleans. Presentation details are below:

Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.

Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

Cardiovascular Systems

Inotiv, Inc.

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Data Published in Cancer Research, a journal of the American Association for Cancer Research

Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss

New York, NY, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology, today announced the closing of its previously announced upsized initial public offering of 3,200,000 shares of common stock at a public offering price of $5.00 per share, for gross proceeds of $16,000,000, before deducting underwriting discounts and offering expenses.  All of the shares of common stock were offered by Nuvectis.

Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock

Here are a few things that investors in Nuvectis may want to know today, as NVCT stock surges on incredible volume. The post NVCT Stock Alert: 7 Things to Know as Nuvectis Pharma Soars 200% appeared first on InvestorPlace.

NVCT Stock Alert: 7 Things to Know as Nuvectis Pharma Soars 200%

Here's why NVCT stock is moving right now. The post Best Penny Stocks Today: Why NVCT Stock Is Moving 230%+ appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Today: Why NVCT Stock Is Moving 230%+

Arcellx

Murphy Canyon Acquisition Corp

The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings. CAR-T biotech Arcellx priced at the low end to raise $124 million at a $583 million market cap.

U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs

Fort Lee, NJ, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology, today announced the pricing of its initial public offering of 3,200,000 shares of common stock at a public offering price of $5.00 per share, for gross proceeds of $16,000,000, before deducting underwriting discounts and commissions and offering expenses. In addition, the Company has granted the underwriter a 30-day option to purchase additional 480,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock

Biotech company Nuvectis had planned to offer 2.3 million shares at $12 to $14 each.

Nuvectis Pharma Delays Listing as IPO Market Turns Cautious

The U.S. initial public offering market is expected to see just one deal this week, taking a pause after the shortened holiday week. Last week, there was just one IPO and six SPACs, or special purpose acquisition corporations, which raise money and then acquire a business or businesses.

Nuvectis Pharma expected to be sole IPO in U.S. market this week

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

This Week's Scheduled IPOs

News for Nuvectis Pharma Stock (NVCT)